CA2348067A1 - Composition for extending post meal satiety - Google Patents
Composition for extending post meal satiety Download PDFInfo
- Publication number
- CA2348067A1 CA2348067A1 CA002348067A CA2348067A CA2348067A1 CA 2348067 A1 CA2348067 A1 CA 2348067A1 CA 002348067 A CA002348067 A CA 002348067A CA 2348067 A CA2348067 A CA 2348067A CA 2348067 A1 CA2348067 A1 CA 2348067A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- weight
- nutritional composition
- meal
- satiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 235000012054 meals Nutrition 0.000 title claims abstract description 23
- 235000019627 satiety Nutrition 0.000 title claims abstract description 23
- 230000036186 satiety Effects 0.000 title claims abstract description 23
- 235000016709 nutrition Nutrition 0.000 claims abstract description 26
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract description 15
- 244000061456 Solanum tuberosum Species 0.000 claims abstract description 13
- 235000002595 Solanum tuberosum Nutrition 0.000 claims abstract description 13
- 235000012015 potatoes Nutrition 0.000 claims abstract description 10
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000019789 appetite Nutrition 0.000 claims abstract description 5
- 230000036528 appetite Effects 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 3
- 159000000007 calcium salts Chemical class 0.000 claims abstract 2
- 239000003086 colorant Substances 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 2
- 239000000975 dye Substances 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- 235000009434 Actinidia chinensis Nutrition 0.000 claims 1
- 244000298697 Actinidia deliciosa Species 0.000 claims 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 claims 1
- 244000144730 Amygdalus persica Species 0.000 claims 1
- 244000099147 Ananas comosus Species 0.000 claims 1
- 235000007119 Ananas comosus Nutrition 0.000 claims 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims 1
- 244000241235 Citrullus lanatus Species 0.000 claims 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 claims 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims 1
- 235000005979 Citrus limon Nutrition 0.000 claims 1
- 244000131522 Citrus pyriformis Species 0.000 claims 1
- 241000675108 Citrus tangerina Species 0.000 claims 1
- 235000015001 Cucumis melo var inodorus Nutrition 0.000 claims 1
- 240000002495 Cucumis melo var. inodorus Species 0.000 claims 1
- 241000220225 Malus Species 0.000 claims 1
- 235000011430 Malus pumila Nutrition 0.000 claims 1
- 235000015103 Malus silvestris Nutrition 0.000 claims 1
- 244000246386 Mentha pulegium Species 0.000 claims 1
- 235000016257 Mentha pulegium Nutrition 0.000 claims 1
- 235000004357 Mentha x piperita Nutrition 0.000 claims 1
- 240000008790 Musa x paradisiaca Species 0.000 claims 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- 244000007021 Prunus avium Species 0.000 claims 1
- 235000010401 Prunus avium Nutrition 0.000 claims 1
- 241001290151 Prunus avium subsp. avium Species 0.000 claims 1
- 235000006040 Prunus persica var persica Nutrition 0.000 claims 1
- 235000014441 Prunus serotina Nutrition 0.000 claims 1
- 240000007651 Rubus glaucus Species 0.000 claims 1
- 235000011034 Rubus glaucus Nutrition 0.000 claims 1
- 235000009122 Rubus idaeus Nutrition 0.000 claims 1
- 235000011941 Tilia x europaea Nutrition 0.000 claims 1
- 240000006909 Tilia x europaea Species 0.000 claims 1
- 240000001717 Vaccinium macrocarpon Species 0.000 claims 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims 1
- 235000009754 Vitis X bourquina Nutrition 0.000 claims 1
- 235000012333 Vitis X labruscana Nutrition 0.000 claims 1
- 240000006365 Vitis vinifera Species 0.000 claims 1
- 235000014787 Vitis vinifera Nutrition 0.000 claims 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 claims 1
- 235000019693 cherries Nutrition 0.000 claims 1
- 235000017803 cinnamon Nutrition 0.000 claims 1
- 235000004634 cranberry Nutrition 0.000 claims 1
- 235000012907 honey Nutrition 0.000 claims 1
- 235000001050 hortel pimenta Nutrition 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- 239000004571 lime Substances 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 150000004668 long chain fatty acids Chemical class 0.000 abstract description 3
- 101800001982 Cholecystokinin Proteins 0.000 description 16
- 102100025841 Cholecystokinin Human genes 0.000 description 16
- 229940107137 cholecystokinin Drugs 0.000 description 16
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 16
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 235000003642 hunger Nutrition 0.000 description 7
- 230000037406 food intake Effects 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 229960005069 calcium Drugs 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000019525 fullness Nutrition 0.000 description 4
- 229920001592 potato starch Polymers 0.000 description 4
- 229940122618 Trypsin inhibitor Drugs 0.000 description 3
- 101710162629 Trypsin inhibitor Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000021196 dietary intervention Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 150000004667 medium chain fatty acids Chemical class 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 239000002753 trypsin inhibitor Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101100298225 Caenorhabditis elegans pot-2 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101710150887 Cholecystokinin A Proteins 0.000 description 1
- 229940122644 Chymotrypsin inhibitor Drugs 0.000 description 1
- 101710137926 Chymotrypsin inhibitor Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010016338 Feeling jittery Diseases 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 101710112930 Trypsin inhibitor 1 Proteins 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- RUGLKMZEADWYCJ-KVVVOXFISA-N calcium;(z)-octadec-9-enoic acid Chemical compound [Ca].CCCCCCCC\C=C/CCCCCCCC(O)=O RUGLKMZEADWYCJ-KVVVOXFISA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019553 satiation Nutrition 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pediatric Medicine (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
A nutritional composition in a dry powder form including an extract of potatoes that provides a source of proteinase inhibitor that is mixed with water and ingested before a meal which extends satiety and thereby reduces appetite. The nutritional composition includes between about 10 % and about 80 % by weight of a protein, between about 10 % and about 40 % by weight of a medium to long chain fatty acid, between about 2 % and about 5 % by weight o f a calcium salt, and between about 1 % and about 5 % by weight of a proteinas e inhibitor provided by the extract of potatoes.
Description
COMPOSITION FOR EXTENDING POST MEAL SATIETY
BACKGROUND OF THE INVENTION
Field of Invention The present invention relates to a nutritional composition for extending satiety following a meal. More particularly the nutritional composition includes protein, medium and/or long chain fatty acids and calcium to stimulate the secretion of cholecystokinin a gastric peptide, and a source ofproteinase inhibitor extracted from potatoes that prevents the breakdown of cholecystokinin. By increasing and sustaining the levels of cholecystokinin, the present invention extends satiety.
Back.~round of the Prior Art Over the last forty years there has been extensive research conducted on mechanisms that would extend satiety following the ingestion of a meal. The benefits of such an invention have obvious utility in producing weight loss. Weight loss research has focused on three areas.
1 ~ Because the brain plays an essential role in the control of appetite, researchers have looked at various neurotransmitters, specifically, serotonin, dopamine and nor-epinephrine. A number of prescription and over-the-counter products have been developed which influence these neurotransmitters, thereby reducing appetite. Reducing appetite pharmacologically has a number of drawbacks, including a loss of effectiveness over a period of time. Drugs that affect neurotransmitters also affect the central nervous systems and can cause jitteriness and anxiety. In addition, these agents can produce cardiovascular effects that may even be fatal.
A second approach has focused on slowing gastric emptying thereby creating a feeling of fullness. This approach utilizes insoluble fibers, which slow the movement of food through the gastrointestinal tract. The disadvantage with the use of fiber is that the quantities needed to 2s produce an effect create an unpalatable diet as well as numerous gastrointestinal effects including bloating, gas and diarrhea.
A third approach investigates stimulating the body's satiety mechanism. When food is consumed a peptide is released called Cholecystokinin Releasing Protein (CCK-RP).
Cholecystokinin Releasing Protein then stimulates the release of cholecystokinin in the gut.
Cholecystokinin has been shown to increase satiety. When cholecystokinin is released it also stimulates the release of enzymes which inactivate CCK-RP. When CCK-RP is inactivated, CCK levels drop and the feeling of satiation is diminished. Studies have shown that cholecystokinin is extremely effective in extending satiety following ingestion of a meal.
Although CCK has been shown to extend satiety and reduce food intake, a major disadvantage is that it must be given intravenously. When administered orally, CCK is inactivated by gastric enzymes. This has severely limited its use as a potential weight loss agent.
A number of nutritive agents can stimulate the release of cholecystokinin.
Researchers have shown that protein, fat (particularly medium chain fatty acids), and calcium stimulate the release of CCK.
United States Patent No. 4,491,78 discloses the oral administration of a trypsin inhibitor 1 ~ to stimulate satiety by stimulating the release of cholecystokinin. The trypsin inhibitor was postulated to act by inhibiting the negative feedback signal for cholecystokinin secretion. In this fashion, the trypsin inhibitor sustained levels of cholecystokinin thereby extending satiety.
A number of studies have shown that proteinase inhibitor extracted from potatoes stimulates the release of cholecystokinin.
There is a definite need in the art for a nutritional intervention composition that can be taken orally, stimulate cholecystokinin levels prior to the initiation of a meal and sustain cholecystokinin levels and satiety for an extended period following consumption of a meal. An important element of this invention is the design of a product taken in a specified interval prior to the commencement of a meal. Thus, satiety levels are already enhanced before the meal, 2~ decreasing the quantity of food consumed during that meal.
SUMMARY OF THE INVENTION
The present invention provides for nutritional composition in a dry powder form for extending satiety following ingestion of a meal.
The dry nutritional composition includes proteins in the range of 10% to 80%.
The protein can be in the form of soy, whey, casein or a specific amino acid mixture containing essential amino acids or of the amino acid phenylalanine.
The dry nutritional composition also includes the mineral calcium in the range of 2% to 6%. The calcium can be in the form of a salt including calcium chloride, calcium carbonate, calcium lactate etc.
The dry nutritional composition also includes medium and/or long chain fatty acids (Cz2-C») in the range of 10°~0-40%.
The dry nutritional composition also includes a source of proteinase inhibitor extracted from potatoes wherein the protease inhibitor is present in the range of 0.02%-5%.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a graphical representation of the responses of test subjects as to their feeling of satiety taken in fifteen minute intervals over a three and one-half hour period following a meal, showing both subjects who were administered a placebo and subjects who were administered a nutritional supplement according to the present invention.
Fig. 2 is a graphical representation of the responses of test subjects as to their feeling of hunger taken in fifteen minute intervals over a three and one-half hour period following a meal, showing both subjects who were administered a placebo and subjects who were administered a nutritional supplement according to the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The nutritional composition for nutritional intervention for extending satiety includes nutritional agents being protein, medium and/or chain fatty acids, calcium, an extract ofpotatoes 2~ containing proteinase inhibitor, and, in a preferred form, flavoring agents and coloring agents.
The proteinase inhibitor is a heat stable protein present in potatoes and in extracts from potatoes and has a molecular weight of approximately 21,000. It is both a trypsin and chymotrypsin inhibitor, with its critical functionality being that it stimulates the release of cholecystokinin.
The protease inhibitor with the desired activity is present in potatoes and in more concentrated form in commercially available extracts or fractions of potatoes, such as coarse potato flour and potato fiber. Specifically, coarse potato flour available from Nonpariel Company contains approximately 0.49 mg of potato protease inhibitor two per gram, and Paselli PPC potato flour available from Avebe Company, The Netherlands, contains about 1.35 mg potato protease inhibitor rivo per gram. A method of extraction of a relatively pure proteinase inhibitor with the desired activity of the present invention is described in Bryant, J., Green, T. R., Gurusaddalah, T., and Ryan, C. A. {1976), Biochem. I5, 3418.
Experiment 1 This study was conducted with 21 subjects having a mean BMI =31.2 kglm2 (range 27.0 - 35.8) and mean age = 30.9 years (range 22 - 45). The study was a cross over design consisting of two parts. In the first phase the subjects were either given a placebo whose isocaloric I ~ composition was equal to the nutritional drink composition or the nutritional drink composition.
Both treatments were administered in 8 oz. of water 15 minutes prior to the meal. The meal consisted of 460 calories. Subjects were required to consume the meal within 15 minutes.
Following the consumption of the meal subjects were asked to rate their feelings of hunger and satiety on 6 visual analog scales every 15 minutes for 3 '/2 hours.
The nutritional drink composition is set out below:
wo ovmsa~ Pcr~usoonois~
Nutritional Drink Composition Constituent Grams %
Whey Protein 13.00 71.5 Non-Dairy Creamer4.00 22.0 containing 50% oleic acid Calcium Lactate0.635 3.5 Flavor 0.19 1.0 Color 0.05 0.3 POT 2' 0.30 1.7 ~ POT ? includes10% by weight einase approx. of the prot inhibitor Hunger ratings following ingestion of the nutritional drink composition were significantly decreased throughout the post-meal measurement period, reaching a 30% decrease by 3 hours post meal (p=0.033). Consistent with this finding, fullness ratings were significantly greater starting 3 hours post meal (37% increase, p=0.043). No differences in subjective ratings of other hunger-related items, or in thirst, were observed between the conditions.
Accordingly, an advantage of the present invention is that it provides for a nutritional intervention composition for extending satiety and reducing hunger following the termination of a meal.
Experiment 2:
This study was conducted with 21 subjects having a mean BMI =31.2 kg/mZ (range 27.0 I ~ - 35.8) and mean age = 30.9 years (range 22 - 45). During the diet, subjects drank 8 oz. (80 kcal) of the nutritional drink composition of Experiment 1 twice daily fifteen minutes before lunch and dinner. The effect of the nutritional drink composition on satiety was measured in a laboratory before and in the fourth week of the diet. On separate days subjects ingested the nutritional drink composition beverage or a placebo beverage (matched for volume and energy) fifteen minutes before a 350 calorie meal. Subjects rated hunger and fullness on visual analog scales every 1 S minutes for 3 '/2 hours.
The results of the study show that after four weeks on the diet, fullness ratings after lunch were higher after the consumption of the nutritional drink composition than the placebo beverage (mean ~ SD for alI time intervals = 71.0 t 17.3 vs. 65.5 ~ 16.7, p < 0.05).
Hunger ratings were 32% lower after the protease inhibitor than the placebo beverage (10.5 t 12.0 vs. 15.4 t 13.3, p < 0.01 ). There were no adverse reactions to the nutritional drink composition, and subjects reported that it helped them to reduce their food intake. Weight loss was significant (2.0 t 1.1 kg in 4 weeks, p < 0.001 ).
Accordingly an advantage of the present invention is that it provides continual effectiveness over a 30-day period and by extending satiety results in significant weight loss.
I 0 The source of the protease inhibitor may vary depending on the particular application for the satiety extending product of the present invention. For example, while coarse potato flour contains a significant amount of the protease inhibitor, it is difficult to disperse in water. Those having ordinary skill in the art, following the teachings of the invention set out above can readily accomplish determining an appropriate source of protease inhibitor as well as other components 15 that may be added to the composition to improve characteristics such as mouth feel, taste, and the like. Although the description above contains many specificities, these should not be construed as limiting the scope of the invention, but as merely providing illustrations of some of the presently preferred embodiments of this invention.
BACKGROUND OF THE INVENTION
Field of Invention The present invention relates to a nutritional composition for extending satiety following a meal. More particularly the nutritional composition includes protein, medium and/or long chain fatty acids and calcium to stimulate the secretion of cholecystokinin a gastric peptide, and a source ofproteinase inhibitor extracted from potatoes that prevents the breakdown of cholecystokinin. By increasing and sustaining the levels of cholecystokinin, the present invention extends satiety.
Back.~round of the Prior Art Over the last forty years there has been extensive research conducted on mechanisms that would extend satiety following the ingestion of a meal. The benefits of such an invention have obvious utility in producing weight loss. Weight loss research has focused on three areas.
1 ~ Because the brain plays an essential role in the control of appetite, researchers have looked at various neurotransmitters, specifically, serotonin, dopamine and nor-epinephrine. A number of prescription and over-the-counter products have been developed which influence these neurotransmitters, thereby reducing appetite. Reducing appetite pharmacologically has a number of drawbacks, including a loss of effectiveness over a period of time. Drugs that affect neurotransmitters also affect the central nervous systems and can cause jitteriness and anxiety. In addition, these agents can produce cardiovascular effects that may even be fatal.
A second approach has focused on slowing gastric emptying thereby creating a feeling of fullness. This approach utilizes insoluble fibers, which slow the movement of food through the gastrointestinal tract. The disadvantage with the use of fiber is that the quantities needed to 2s produce an effect create an unpalatable diet as well as numerous gastrointestinal effects including bloating, gas and diarrhea.
A third approach investigates stimulating the body's satiety mechanism. When food is consumed a peptide is released called Cholecystokinin Releasing Protein (CCK-RP).
Cholecystokinin Releasing Protein then stimulates the release of cholecystokinin in the gut.
Cholecystokinin has been shown to increase satiety. When cholecystokinin is released it also stimulates the release of enzymes which inactivate CCK-RP. When CCK-RP is inactivated, CCK levels drop and the feeling of satiation is diminished. Studies have shown that cholecystokinin is extremely effective in extending satiety following ingestion of a meal.
Although CCK has been shown to extend satiety and reduce food intake, a major disadvantage is that it must be given intravenously. When administered orally, CCK is inactivated by gastric enzymes. This has severely limited its use as a potential weight loss agent.
A number of nutritive agents can stimulate the release of cholecystokinin.
Researchers have shown that protein, fat (particularly medium chain fatty acids), and calcium stimulate the release of CCK.
United States Patent No. 4,491,78 discloses the oral administration of a trypsin inhibitor 1 ~ to stimulate satiety by stimulating the release of cholecystokinin. The trypsin inhibitor was postulated to act by inhibiting the negative feedback signal for cholecystokinin secretion. In this fashion, the trypsin inhibitor sustained levels of cholecystokinin thereby extending satiety.
A number of studies have shown that proteinase inhibitor extracted from potatoes stimulates the release of cholecystokinin.
There is a definite need in the art for a nutritional intervention composition that can be taken orally, stimulate cholecystokinin levels prior to the initiation of a meal and sustain cholecystokinin levels and satiety for an extended period following consumption of a meal. An important element of this invention is the design of a product taken in a specified interval prior to the commencement of a meal. Thus, satiety levels are already enhanced before the meal, 2~ decreasing the quantity of food consumed during that meal.
SUMMARY OF THE INVENTION
The present invention provides for nutritional composition in a dry powder form for extending satiety following ingestion of a meal.
The dry nutritional composition includes proteins in the range of 10% to 80%.
The protein can be in the form of soy, whey, casein or a specific amino acid mixture containing essential amino acids or of the amino acid phenylalanine.
The dry nutritional composition also includes the mineral calcium in the range of 2% to 6%. The calcium can be in the form of a salt including calcium chloride, calcium carbonate, calcium lactate etc.
The dry nutritional composition also includes medium and/or long chain fatty acids (Cz2-C») in the range of 10°~0-40%.
The dry nutritional composition also includes a source of proteinase inhibitor extracted from potatoes wherein the protease inhibitor is present in the range of 0.02%-5%.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a graphical representation of the responses of test subjects as to their feeling of satiety taken in fifteen minute intervals over a three and one-half hour period following a meal, showing both subjects who were administered a placebo and subjects who were administered a nutritional supplement according to the present invention.
Fig. 2 is a graphical representation of the responses of test subjects as to their feeling of hunger taken in fifteen minute intervals over a three and one-half hour period following a meal, showing both subjects who were administered a placebo and subjects who were administered a nutritional supplement according to the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The nutritional composition for nutritional intervention for extending satiety includes nutritional agents being protein, medium and/or chain fatty acids, calcium, an extract ofpotatoes 2~ containing proteinase inhibitor, and, in a preferred form, flavoring agents and coloring agents.
The proteinase inhibitor is a heat stable protein present in potatoes and in extracts from potatoes and has a molecular weight of approximately 21,000. It is both a trypsin and chymotrypsin inhibitor, with its critical functionality being that it stimulates the release of cholecystokinin.
The protease inhibitor with the desired activity is present in potatoes and in more concentrated form in commercially available extracts or fractions of potatoes, such as coarse potato flour and potato fiber. Specifically, coarse potato flour available from Nonpariel Company contains approximately 0.49 mg of potato protease inhibitor two per gram, and Paselli PPC potato flour available from Avebe Company, The Netherlands, contains about 1.35 mg potato protease inhibitor rivo per gram. A method of extraction of a relatively pure proteinase inhibitor with the desired activity of the present invention is described in Bryant, J., Green, T. R., Gurusaddalah, T., and Ryan, C. A. {1976), Biochem. I5, 3418.
Experiment 1 This study was conducted with 21 subjects having a mean BMI =31.2 kglm2 (range 27.0 - 35.8) and mean age = 30.9 years (range 22 - 45). The study was a cross over design consisting of two parts. In the first phase the subjects were either given a placebo whose isocaloric I ~ composition was equal to the nutritional drink composition or the nutritional drink composition.
Both treatments were administered in 8 oz. of water 15 minutes prior to the meal. The meal consisted of 460 calories. Subjects were required to consume the meal within 15 minutes.
Following the consumption of the meal subjects were asked to rate their feelings of hunger and satiety on 6 visual analog scales every 15 minutes for 3 '/2 hours.
The nutritional drink composition is set out below:
wo ovmsa~ Pcr~usoonois~
Nutritional Drink Composition Constituent Grams %
Whey Protein 13.00 71.5 Non-Dairy Creamer4.00 22.0 containing 50% oleic acid Calcium Lactate0.635 3.5 Flavor 0.19 1.0 Color 0.05 0.3 POT 2' 0.30 1.7 ~ POT ? includes10% by weight einase approx. of the prot inhibitor Hunger ratings following ingestion of the nutritional drink composition were significantly decreased throughout the post-meal measurement period, reaching a 30% decrease by 3 hours post meal (p=0.033). Consistent with this finding, fullness ratings were significantly greater starting 3 hours post meal (37% increase, p=0.043). No differences in subjective ratings of other hunger-related items, or in thirst, were observed between the conditions.
Accordingly, an advantage of the present invention is that it provides for a nutritional intervention composition for extending satiety and reducing hunger following the termination of a meal.
Experiment 2:
This study was conducted with 21 subjects having a mean BMI =31.2 kg/mZ (range 27.0 I ~ - 35.8) and mean age = 30.9 years (range 22 - 45). During the diet, subjects drank 8 oz. (80 kcal) of the nutritional drink composition of Experiment 1 twice daily fifteen minutes before lunch and dinner. The effect of the nutritional drink composition on satiety was measured in a laboratory before and in the fourth week of the diet. On separate days subjects ingested the nutritional drink composition beverage or a placebo beverage (matched for volume and energy) fifteen minutes before a 350 calorie meal. Subjects rated hunger and fullness on visual analog scales every 1 S minutes for 3 '/2 hours.
The results of the study show that after four weeks on the diet, fullness ratings after lunch were higher after the consumption of the nutritional drink composition than the placebo beverage (mean ~ SD for alI time intervals = 71.0 t 17.3 vs. 65.5 ~ 16.7, p < 0.05).
Hunger ratings were 32% lower after the protease inhibitor than the placebo beverage (10.5 t 12.0 vs. 15.4 t 13.3, p < 0.01 ). There were no adverse reactions to the nutritional drink composition, and subjects reported that it helped them to reduce their food intake. Weight loss was significant (2.0 t 1.1 kg in 4 weeks, p < 0.001 ).
Accordingly an advantage of the present invention is that it provides continual effectiveness over a 30-day period and by extending satiety results in significant weight loss.
I 0 The source of the protease inhibitor may vary depending on the particular application for the satiety extending product of the present invention. For example, while coarse potato flour contains a significant amount of the protease inhibitor, it is difficult to disperse in water. Those having ordinary skill in the art, following the teachings of the invention set out above can readily accomplish determining an appropriate source of protease inhibitor as well as other components 15 that may be added to the composition to improve characteristics such as mouth feel, taste, and the like. Although the description above contains many specificities, these should not be construed as limiting the scope of the invention, but as merely providing illustrations of some of the presently preferred embodiments of this invention.
Claims (5)
1. A nutritional composition in a dry powder form that is mixed with water and ingested before a meal which extends satiety and thereby reduces appetite, comprising:
(a) a protein comprising between about 10% and about 80% by weight of said dry composition;
(b) one or more fatty acids comprising between about 10% and about 40% by weight of said dry composition;
(c) a calcium salt comprising between about 2% and about 5% by weight of said dry composition; and (d) an extract of potatoes providing a source of proteinase inhibitor that comprises between about 0.02% and about 5% by weight of said dry composition.
(a) a protein comprising between about 10% and about 80% by weight of said dry composition;
(b) one or more fatty acids comprising between about 10% and about 40% by weight of said dry composition;
(c) a calcium salt comprising between about 2% and about 5% by weight of said dry composition; and (d) an extract of potatoes providing a source of proteinase inhibitor that comprises between about 0.02% and about 5% by weight of said dry composition.
2. A nutritional composition as defined in claim 1, wherein said fatty acid comprises oleic acid.
3. A nutritional composition as defined in claim 1, further comprising a water soluble flavoring selected from the group including natural extracts and artificially produced extract components of apple, banana, cherry, cinnamon, cranberry, grape, honeydew, honey, kiwi, lemon, lime, orange, peach, peppermint, pineapple, raspberry, tangerine, watermelon, and wild cherry.
4. A nutritional composition as defined in claim 1, further comprising a colorant selected from the group including water soluble natural or artificial dyes of blue, green, orange, red, violet, and yellow.
5. A nutritional composition as defined in claim 1, further comprising a colorant selected from the group including iron oxide dyes, ultramarine pigments of blue, pink, red, and violet.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14589299P | 1999-07-27 | 1999-07-27 | |
| US60/145,892 | 1999-07-27 | ||
| PCT/US2000/020157 WO2001017541A1 (en) | 1999-07-27 | 2000-07-25 | Composition for extending post meal satiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2348067A1 true CA2348067A1 (en) | 2001-03-15 |
Family
ID=22515008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002348067A Abandoned CA2348067A1 (en) | 1999-07-27 | 2000-07-25 | Composition for extending post meal satiety |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1115409A4 (en) |
| JP (2) | JP2003508490A (en) |
| KR (1) | KR20010075394A (en) |
| AU (1) | AU779377C (en) |
| BR (1) | BR0006959A (en) |
| CA (1) | CA2348067A1 (en) |
| MX (1) | MXPA01003054A (en) |
| WO (1) | WO2001017541A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6686456B2 (en) | 2001-07-06 | 2004-02-03 | Kemin Foods, L.C. | Method for the elimination of Kunitz and Bowman-Birk trypsin inhibitors and carboxypeptidase inhibitor from potato proteins |
| JP2005015358A (en) * | 2003-06-25 | 2005-01-20 | Pharma Design Inc | Medicinal composition used for treating eating disorder |
| AU2006235407B2 (en) * | 2005-04-11 | 2011-02-24 | University Of Tennessee Research Foundation | Stable dairy components effective for fat loss |
| JP2010094085A (en) * | 2008-10-17 | 2010-04-30 | Pola Chem Ind Inc | Food composition for dieting use |
| JP5691105B2 (en) * | 2009-01-30 | 2015-04-01 | 株式会社東洋新薬 | Taste improvement method of food containing potato extract |
| DK2227966T3 (en) * | 2009-02-25 | 2016-09-12 | Coöperatie Avebe U A | Spice |
| JP5672588B2 (en) * | 2009-05-26 | 2015-02-18 | 株式会社東洋新薬 | Diet composition |
| JP5721232B2 (en) * | 2009-12-04 | 2015-05-20 | 株式会社東洋新薬 | Glucagon-like peptide-1 secretion promoter |
| CN107334875A (en) * | 2017-08-30 | 2017-11-10 | 南宁学院 | A kind of medicinal liquor for treating diarrhoea and preparation method thereof |
| CN111493254A (en) * | 2020-04-10 | 2020-08-07 | 苏州绿叶日用品有限公司 | A solid beverage containing rhizoma Solani Tuber osi extract and its preparation method |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4491578A (en) * | 1982-06-14 | 1985-01-01 | Peikin Steven R | Method of stimulating satiety in mammals |
| US4833128A (en) * | 1984-12-28 | 1989-05-23 | Neil Solomon | Dietary supplement |
| JPH0699321B2 (en) * | 1990-01-22 | 1994-12-07 | 不二製油株式会社 | Appetite suppressant and food containing the same |
| US5468727A (en) * | 1990-12-13 | 1995-11-21 | Board Of Regents, The University Of Texas System | Methods of normalizing metabolic parameters in diabetics |
| US5221668A (en) * | 1992-02-26 | 1993-06-22 | Abbott Laboratories | Nutritional product for trauma and surgery patients |
| NZ260933A (en) * | 1993-07-16 | 1996-07-26 | Hercules Inc | Cation-complexed polysaccharides; use in foods and pharmaceuticals |
| US5340603A (en) * | 1993-08-30 | 1994-08-23 | Abbott Laboratories | Nutritional product for human infants having chronic lung disease |
| KR100406912B1 (en) * | 1994-08-05 | 2004-02-18 | 위스콘신 얼럼나이 리서어치 화운데이션 | CCK Antibodies Used to Improve Feed Efficiency |
| US5595772A (en) * | 1995-06-07 | 1997-01-21 | Massachusetts Institute Of Technology | Composition and methods for losing weight |
| EP1310173B2 (en) * | 1997-06-23 | 2014-12-31 | Société des Produits Nestlé S.A. | Composition for providing nutrition to diabetics |
| US6475539B1 (en) * | 1998-05-07 | 2002-11-05 | Abbott Laboratories | Nutritionally complete low pH enteral formula |
| US6051236A (en) * | 1998-11-12 | 2000-04-18 | Pacifichealth Laboratories, Inc. | Composition for optimizing muscle performance during exercise |
| US6025363A (en) * | 1998-11-17 | 2000-02-15 | Giles, Jr.; James A. | Composition for suppressing appetite |
-
2000
- 2000-07-25 EP EP00950624A patent/EP1115409A4/en not_active Withdrawn
- 2000-07-25 WO PCT/US2000/020157 patent/WO2001017541A1/en not_active Application Discontinuation
- 2000-07-25 BR BR0006959-0A patent/BR0006959A/en not_active IP Right Cessation
- 2000-07-25 KR KR1020017003896A patent/KR20010075394A/en not_active Application Discontinuation
- 2000-07-25 AU AU63704/00A patent/AU779377C/en not_active Ceased
- 2000-07-25 CA CA002348067A patent/CA2348067A1/en not_active Abandoned
- 2000-07-25 JP JP2001521331A patent/JP2003508490A/en active Pending
- 2000-07-25 MX MXPA01003054A patent/MXPA01003054A/en active IP Right Grant
-
2005
- 2005-08-15 JP JP2005235268A patent/JP2005336208A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU6370400A (en) | 2001-04-10 |
| JP2005336208A (en) | 2005-12-08 |
| MXPA01003054A (en) | 2003-07-14 |
| AU779377C (en) | 2005-06-30 |
| WO2001017541A1 (en) | 2001-03-15 |
| JP2003508490A (en) | 2003-03-04 |
| KR20010075394A (en) | 2001-08-09 |
| EP1115409A1 (en) | 2001-07-18 |
| EP1115409A4 (en) | 2005-04-13 |
| AU779377B2 (en) | 2005-01-20 |
| BR0006959A (en) | 2001-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6838431B2 (en) | Nutritional intervention composition containing a source of proteinase inhibitor extending post meal satiety | |
| CN101061860B (en) | Leucine-rich nutritional compositions | |
| US6383482B1 (en) | Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus | |
| JP2005336208A (en) | Composition for extending post meal satiety | |
| CN101212961A (en) | HMB compositions and uses thereof | |
| AU2003287974B2 (en) | Blood glucose regulating composition | |
| US8388949B2 (en) | Compositions comprising pantothenic acid and their use for stimulating appetite | |
| JP2003523368A (en) | Nutrition intervention compositions to increase and maintain satiety | |
| US20060153898A1 (en) | Nocturnal muscle enhancing composition and method | |
| GB2323531A (en) | Serenoa Repens | |
| TW200812503A (en) | Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass | |
| US8722614B2 (en) | Adiponectin production enhancer | |
| EP1358878A1 (en) | Remedies/preventives for inflammatory diseases | |
| CN102711803A (en) | GLP-2 for use in intestine and muscle recovery | |
| US20040077530A1 (en) | Composition for reducing caloric intake | |
| US20040097429A1 (en) | Method for the reduction of the mammalian appetite | |
| JP4300753B2 (en) | Anemia suppressor and appetite suppressant | |
| Giampapa | Every man takes the limits of his own field of vision for the limits of the world. | |
| JP2023116763A (en) | Compositions for improving insulin resistance | |
| Ohki et al. | The Japanese nutritional health beverage market | |
| Furber | Nutrition, Diet, and Supplements for Peak Physical & Mental Performance | |
| TW201021820A (en) | Formulations and methods for increasing metabolic rate, burning calories, thermogenesis and total weight control |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |